BioXcel Therapeutics, Inc. 8-K

What Happened
BioXcel Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 and provided a business update via a press release issued on May 15, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8-K (filed May 15, 2026), which is incorporated by reference into the filing.

Key Details

• Filing date: May 15, 2026; the press release covers quarterly results for the period ended March 31, 2026.
• The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K includes Inline XBRL cover page tags (interactive data) per the exhibits disclosure.

Why It Matters
This 8-K notifies investors that BioXcel has released its latest quarterly earnings and a business update—information investors use to assess recent performance, revenue/earnings trends, cash position, and near-term priorities. Investors should read the Exhibit 99.1 press release for the specific financial figures and operational details reported for Q1 2026.